Time Course of C-Reactive Protein Reduction With Simvastatin Therapy in Patients With Type 2 Diabetes Mellitus

American Journal of Cardiology

Volumn 98, Issue 12, 2006, Pages 1656-1659

  Hernandez, Teri L ^a   Capell, Warren H ^a   Wolfe, Pamela ^a   Gerard, Lori A ^a   Eckel, Robert H ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; SIMVASTATIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONOPHARMACOLOGY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; LIPID ANALYSIS; MALE; MEASUREMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; SIMVASTATIN;

EID: 37849189127     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.07.047     Document Type: Article

References (15)

1. Schulze M.B., Rimm E.B., Li T., Rifai N., Stampfer M.J., and Hu F.B. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 27 (2004) 889-894
2. Plenge J.K., Hernandez T.L., Weil K.M., Poirier P., Grunwald G.K., Marcovina S.M., and Eckel R.H. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 106 (2002) 1447-1452
3. NCEP Expert Panel. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
4. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
5. Verbeke G., and Molenberghs G. Linear Mixed Models in Practice: A SAS Oriented Approach (1997), Springer, New York
6. Laird N.M., and Ware J.H. Random-effects models for longitudinal data. Biometrics 38 (1982) 963-974
7. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., and Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100 (1999) 230-235
8. Kinlay S., Timms T., Clark M., Karam C., Bilodeau T., Ridker P.M., Rifai N., Carlson W., Lloyd-Jones D.M., Johnstone M., et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol 89 (2002) 1205-1207
9. Ridker P.M., Rifai N., Clearfield M., Downs J.R., Weis S.E., Miles J.S., and Gotto Jr. A.M. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344 (2001) 1959-1965
10. Albert M.A., Danielson E., Rifai N., and Ridker P.M. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 286 (2001) 64-70
11. de Lemos J.A., Blazing M.A., Wiviott S.D., Lewis E.F., Fox K.A., White H.D., Rouleau J.L., Pedersen T.R., Gardner L.H., Mukherjee R., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292 (2004) 1307-1316
12. Ridker P.M., Rifai N., and Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 103 (2001) 1191-1193
13. Jialal I., Stein D., Balis D., Grundy S.M., Adams-Huet B., and Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103 (2001) 1933-1935
14. Tan K.C., Chow W.S., Tam S.C., Ai V.H., Lam C.H., and Lam K.S. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 87 (2002) 563-568
15. van de Ree M.A., Huisman M.V., Princen H.M., Meinders A.E., and Kluft C. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 166 (2003) 129-135